Issued on behalf of Avant Technologies Inc.
VANCOUVER – Baystreet.ca News Commentary – AI is rewriting the rules of healthcare—not in a burst, but in a careful, calculated march that balances innovation with caution. That same tension is playing out in statehouses like Connecticut’s, where lawmakers are weighing how to regulate AI while also addressing the urgent needs of a strained healthcare workforce. Meanwhile, OpenAI just took its biggest step yet into health tech by releasing HealthBench, a benchmark dataset designed to test how well large language models can answer medical questions. Amid this flurry of policy, infrastructure, and research activity, several public companies are emerging as early leaders at the intersection of generative AI and healthcare—among them Avant Technologies, Inc. (OTCQB: AVAI), Amazon.com, Inc. (NASDAQ: AMZN), Royal Philips (NYSE: PHG), NVIDIA Corporation (NASDAQ: NVDA), and Oracle Corporation (NYSE: ORCL).
Analysts at MarketsandMarkets are forecasting the AI in Healthcare Market to surge at a massive 38.6% CAGR to an impressive US$110.61 billion by 2030. By 2035, Accenture analysts believe AI could add another $461 billion in value to a healthcare industry already on track to surpass $2.26 trillion.
Avant Technologies, Inc. (OTCQB: AVAI) is quietly but deliberately advancing its position in AI-powered healthcare through a proposed acquisition of its joint venture partner, Ainnova Tech. The two companies, already aligned under the Ai-nova Acquisition Corp. (AAC) banner, are now moving to unify operations—an intentional step that comes just ahead of their scheduled FDA pre-submission meeting this July. If completed, the merger would remove internal friction, streamline clinical trial planning, and strengthen their regulatory posture ahead of potential U.S. market entry.
“We believe bringing the two companies together will offer tremendous value for shareholders,” said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. “It will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally.”
At the core of this effort is Vision AI, a non-invasive clinical screening platform that combines retinal imaging, vital sign capture, and machine-learning algorithms to detect early signals of chronic illness—including diabetic retinopathy, cardiovascular disease, kidney and liver conditions, and type 2 diabetes. Operating under AAC, the joint venture holds global rights to the platform, which has shown more than 90% sensitivity in early detection, according to NIH-cited research.
“This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where Vision AI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market,” said Vargas. “Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product.”
Unlike many healthcare AI startups still stuck at concept stage, Avant’s technology is already deployed in Latin America—including Chile, Mexico, and Brazil—where it’s being tested in real-world clinical workflows. These field programs are not only helping build a safety and efficacy track record, they’re also providing critical user feedback that shapes the platform’s refinement and usability.
To support broader clinical reach, AAC recently integrated four new diagnostic algorithms into Vision AI. Trained on over 2.3 million clinical cases, these additions enhance the system’s utility across a wider range of chronic conditions. With proven traction abroad and a pending regulatory milestone in the U.S., Avant is moving from potential to presence—and may soon find itself on the radar of a much larger healthcare conversation.
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Amazon.com, Inc. (NASDAQ: AMZN) through AWS, is advancing real-world health applications of generative AI with tools like Health Kaki—a personalized AI companion developed for Singapore’s Ministry of Health.
Powered by AWS Bedrock and Anthropic’s Claude 3.5 Sonnet, Health Kaki delivers diet and exercise recommendations that align with cultural norms, clinical guidelines, and user preferences. Its success in moving from concept to production highlights AWS’s role in building scalable, user-centric healthcare AI. With robust guardrails and modular architecture, AWS is positioning itself as a key infrastructure provider in the global shift toward “well care.”
Royal Philips (NYSE: PHG) has partnered with NVIDIA Corporation (NASDAQ: NVDA) to co-develop a foundational AI model aimed at revolutionizing magnetic resonance (MR) imaging.
“Our AI-powered MRI solutions are already enabling healthcare providers to deliver better care to more people,” said Dr. Ioannis Panagiotelis, Business Leader of MRI at Philips. “By partnering with NVIDIA to build an MR Foundational Model, we’re pioneering a new frontier for medical imaging, one that has the potential to transform the role of MR in the diagnosis and treatment of a wide range of diseases. The benefits for patients and healthcare providers could be enormous.”
The initiative, announced at ISMRM 2025, will leverage NVIDIA’s VISTA-3D and MAISI platforms to create a next-generation diagnostic tool that improves image quality, reduces scan times, and streamlines workflow. The AI-powered model will support features like zero-click scan planning, denoising, and real-time image preview, enhancing speed and accuracy for radiologists. This collaboration positions both companies at the forefront of AI-driven precision imaging, with broad implications for diagnostics and patient care.
Oracle Corporation (NYSE: ORCL) has expanded access to its Oracle Health Clinical AI Agent in Canada, bringing its generative AI-powered documentation assistant to a growing list of medical specialties.
“Time is our most precious, non-renewable resource,” said Erin O’Halloran, vice president and Canada market leader, Oracle Health. “Oracle Health Clinical AI Agent helps to restore the clinician-patient relationship, emphasize focused time with patients, and reduce clinician burnout. The availability of this solution marks another step toward modernizing the country’s health information systems and providing a more digitally connected healthcare ecosystem.”
The platform has already helped U.S. healthcare providers cut documentation time by 30%, freeing up clinicians to focus more on patient care. Integrated directly into Oracle’s electronic health records system, the AI agent drafts notes, navigates patient histories, and suggests next steps in real time.
Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
Baystreet.ca
[email protected]
(250) 661-3391
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.